Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Medical Genetics

Is EXT1 More Severe Than EXT2 in Multiple Osteochondromas?

At a Glance

While EXT1 mutations in Multiple Osteochondromas generally cause more bone bumps and skeletal deformities than EXT2 mutations, disease severity is highly unpredictable. Care is based entirely on your individual symptoms and joint health, not just your specific genetic test result.

If your genetic test shows an EXT1 mutation, you might read that this gene is associated with a more severe form of Multiple Osteochondromas (MO), also known as Hereditary Multiple Exostoses (HME). On average, people with an EXT1 mutation do tend to develop a higher number of bone bumps (osteochondromas) and experience more joint and skeletal deformities compared to those with an EXT2 mutation [1][2][3]. However, your specific gene mutation does not dictate your destiny. The severity of this condition varies wildly—even among family members who share the exact same genetic mutation [4][5][6].

How EXT1 and EXT2 Compare

Both EXT1 and EXT2 genes provide instructions for making proteins that help bone and cartilage grow normally. When one of these genes is mutated, the body forms extra bony growths near the joints. While both mutations cause MO, research shows some general differences across large groups of patients:

  • Number of Growths: People with EXT1 mutations typically have a higher total number of osteochondromas than those with EXT2 mutations [1][3].
  • Bone and Joint Impact: EXT1 mutations are often linked to a higher risk of skeletal issues, such as uneven limb lengths, bowing of the forearm bones, and a lower overall height [1][7][8]. Fortunately, when these deformities do occur, orthopedic surgeries are often available to correct them and improve mobility [7][9].
  • Cancer Risk: A major concern for anyone with MO is the 1% to 5% lifetime risk that a benign bone bump could become a cancerous tumor called a chondrosarcoma [10][11][12]. Current evidence does not show a definitive difference in this cancer risk between EXT1 and EXT2 mutations, though doctors may monitor EXT1 patients closely simply because they tend to have more growths to keep track of [12][13].

The Unpredictability of Your Genetics

It is completely normal to feel anxious if you discover you have the “more severe” EXT1 mutation. However, a concept called variable expressivity plays a massive role in this condition [4][6]. This means that the way a genetic mutation physically shows up in your body can be vastly different from how it shows up in someone else.

In fact, there is no reliable way to predict exactly how severe your condition will be based solely on your genetic test [5][14]. Researchers believe that other unmapped modifier genes, alongside environmental factors, heavily influence how the disease progresses [5][4]. Because of this, one sibling with an EXT1 mutation might require multiple surgeries for joint deformities, while another sibling with the exact same mutation might have only a few mild bumps and require no treatment at all [4][5].

(Note: Because MO is an autosomal dominant genetic condition, there is a 50% chance of passing either an EXT1 or EXT2 mutation to your children. Meeting with a genetic counselor can help you understand these family planning implications [4].)

What This Means for Your Care

Because MO is so unpredictable, your medical team will treat you, not just your genetic test results. Clinical management focuses on your specific symptoms, regardless of whether you have an EXT1 or EXT2 mutation [7][9]. You should ideally be monitored by an orthopedic specialist experienced in skeletal dysplasia or bone tumors.

Your care plan will likely involve:

  • Routine Monitoring: You will likely need periodic physical exams and baseline X-rays or MRI scans (often yearly or every few years, depending on your age and symptoms) to track your osteochondromas and joint health [9][15].
  • Symptom Management: Treating any pain, limited movement, or nerve pressure caused by the growths as they arise [7][9].
  • Vigilance for Changes: Benign osteochondromas naturally stop growing when you reach skeletal maturity (typically after puberty) [9]. Therefore, if a bump grows suddenly, changes shape, or becomes painful in adulthood, you should contact your doctor immediately to rule out a rare malignant change [9].

Your genetic test provides helpful background information, but your individual symptoms will guide your journey.

Common questions in this guide

Is an EXT1 mutation always more severe than an EXT2 mutation?
While EXT1 mutations are generally linked to a higher number of bone bumps and skeletal issues, the condition is highly unpredictable. The severity can vary wildly, even among family members who share the exact same genetic mutation.
Does having an EXT1 mutation increase my risk of bone cancer?
People with multiple osteochondromas have a 1% to 5% lifetime risk of a benign bump turning into cancer. Current research does not show a definitive difference in this cancer risk between EXT1 and EXT2 mutations, though doctors may monitor EXT1 patients closely if they have more growths.
Will my treatment be different if I have an EXT1 mutation instead of EXT2?
No, your medical team will treat your specific symptoms rather than just your genetic test results. Your care plan will focus on routine monitoring, managing pain, and utilizing orthopedic surgeries if joint or bone deformities occur.
What should I do if a bone bump starts growing or hurting in adulthood?
Benign bone bumps typically stop growing once you reach skeletal maturity after puberty. If a bump grows suddenly, changes shape, or becomes painful in adulthood, you should contact your doctor immediately to rule out any rare malignant changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Since my genetic test shows an EXT1 mutation, are there specific joints or bones we should be monitoring more closely given the higher risk for deformities?
  2. 2.Which medical specialists (like an orthopedic surgeon or oncologist) should be coordinating my long-term care?
  3. 3.Should I have a baseline imaging scan, such as a skeletal survey or whole-body MRI, to map out all my current osteochondromas?
  4. 4.If I experience new pain or notice a bump growing now that I have reached skeletal maturity, who is the best person on my care team to contact first?
  5. 5.Should my family members undergo genetic testing, and would a referral to a genetic counselor be appropriate for us?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    A genotype-phenotype study of hereditary multiple exostoses in forty-six Chinese patients.

    Li Y, Wang J, Wang Z, et al.

    BMC medical genetics 2017; (18(1)):126 doi:10.1186/s12881-017-0488-2.

    PMID: 29126381
  2. 2

    Mutational spectrum and clinical signatures in 114 families with hereditary multiple osteochondromas: insights into molecular properties of selected exostosin variants.

    Fusco C, Nardella G, Fischetto R, et al.

    Human molecular genetics 2019; (28(13)):2133-2142 doi:10.1093/hmg/ddz046.

    PMID: 30806661
  3. 3

    Assessing the general population frequency of rare coding variants in the EXT1 and EXT2 genes previously implicated in hereditary multiple exostoses.

    Cousminer DL, Arkader A, Voight BF, et al.

    Bone 2016; (92()):196-200 doi:10.1016/j.bone.2016.09.005.

    PMID: 27616605
  4. 4

    Hereditary multiple exostoses: A case report and literature review.

    Ha TH, Ha TMT, Nguyen Van M, et al.

    SAGE open medical case reports 2022; (10()):2050313X221103732 doi:10.1177/2050313X221103732.

    PMID: 35693925
  5. 5

    Hereditary multiple osteochondromas in Jordanian patients: Mutational and immunohistochemical analysis of EXT1 and EXT2 genes.

    Mohaidat Z, Bodoor K, Almomani R, et al.

    Oncology letters 2021; (21(2)):151 doi:10.3892/ol.2020.12412.

    PMID: 33552269
  6. 6

    Identification of Novel EXT Mutations in Patients with Hereditary Multiple Exostoses Using Whole-Exome Sequencing.

    Liang C, Wang YJ, Wei YX, et al.

    Orthopaedic surgery 2020; (12(3)):990-996 doi:10.1111/os.12660.

    PMID: 32293802
  7. 7

    Identification of a novel EXT2 frameshift mutation in a family with hereditary multiple exostoses by whole-exome sequencing.

    Yang M, Xie H, Xu B, et al.

    Journal of clinical laboratory analysis 2021; (35(9)):e23968 doi:10.1002/jcla.23968.

    PMID: 34403521
  8. 8

    Hereditary Multiple Exostoses: a review of clinical appearance and metabolic pattern.

    Beltrami G, Ristori G, Scoccianti G, et al.

    Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases 2016; (13(2)):110-118 doi:10.11138/ccmbm/2016.13.2.110.

    PMID: 27920806
  9. 9

    Secondary peripheral chondrosarcoma in multiple osteochondromas: a retrospective single-institution case series.

    Gnoli M, Gambarotti M, Righi A, et al.

    Orphanet journal of rare diseases 2024; (19(1)):63 doi:10.1186/s13023-023-03006-8.

    PMID: 38351015
  10. 10

    Hereditary multiple exostoses: an educational review.

    Rueda-de-Eusebio A, Gomez-Pena S, Moreno-Casado MJ, et al.

    Insights into imaging 2025; (16(1)):46 doi:10.1186/s13244-025-01899-6.

    PMID: 39982564
  11. 11

    Solitary Osteochondroma at Unusual Sites: A Case Report and Literature Review.

    Alghamdi FA, Aljabri NK, Jafar HM, et al.

    Cureus 2023; (15(11)):e49582 doi:10.7759/cureus.49582.

    PMID: 38156180
  12. 12

    Chondrosarcoma transformation in hereditary multiple exostoses: A systematic review and clinical and cost-effectiveness of a proposed screening model.

    Fei L, Ngoh C, Porter DE

    Journal of bone oncology 2018; (13()):114-122 doi:10.1016/j.jbo.2018.09.011.

    PMID: 30591865
  13. 13

    Is total-body MRI useful as a screening tool to rule out malignant progression in patients with multiple osteochondromas? Results in a single-center cohort of 319 adult patients.

    Van der Woude HJ, Flipsen M, Welsink C, et al.

    Skeletal radiology 2024; (53(1)):141-150 doi:10.1007/s00256-023-04389-2.

    PMID: 37338590
  14. 14

    Phenotypic and Molecular Spectrum of a Turkish Cohort with Hereditary Multiple Osteochondromas.

    Güneş N, Uludağ Alkaya D, Toylu A, et al.

    Turkish archives of pediatrics 2023; (58(4)):376-381 doi:10.5152/TurkArchPediatr.2023.23011.

    PMID: 37317574
  15. 15

    The natural history of multiple osteochondromas in a large Italian cohort of pediatric patients.

    Mordenti M, Shih F, Boarini M, et al.

    Bone 2020; (139()):115499 doi:10.1016/j.bone.2020.115499.

    PMID: 32592948

This page provides educational information on EXT1 and EXT2 genetic mutations. It is not medical advice. Always consult an orthopedic specialist or genetic counselor regarding your specific multiple osteochondromas diagnosis and care plan.

Get notified when new evidence is published on Multiple osteochondromas.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.